Welcome Center  |   Log In  |   Register  |   Follow Us  Facebook  Twitter Google Plus

Latest in Pharmacists

Edmond J. LaVoie, PhD, Professor and Chair of the Department of Medicinal Chemistry at Rutgers University, discusses the potential of a new antibiotic to combat the increasing problems of antibiotic resistance. TAXIS Pharmaceuticals has identified a new...
The common gastric reflux drugs classified as proton pump inhibitors (P.P.I.’s) have been found to increase one’s risk for a heart attack in a study of nearly three million individuals, according to The New York Times. Previous studies found that...
According to Reuters, Ibrance, a breast cancer drug from Pfizer is currently in Phase III clinical trials of a new drug. The drug is designed to treat the most common type of breast cancer, estrogen-receptor positive, human epidermal growth factor...